0001655759-24-000040.txt : 20240321
0001655759-24-000040.hdr.sgml : 20240321
20240321161502
ACCESSION NUMBER: 0001655759-24-000040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240318
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Berkowitz Noah
CENTRAL INDEX KEY: 0001369900
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38672
FILM NUMBER: 24771528
MAIL ADDRESS:
STREET 1: 6 CAMUS DRIVE
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARVINAS, INC.
CENTRAL INDEX KEY: 0001655759
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 472566120
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 WINCHESTER AVE
STREET 2: 5 SCIENCE PARK
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-535-1456
MAIL ADDRESS:
STREET 1: 395 WINCHESTER AVE
STREET 2: 5 SCIENCE PARK
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
FORMER COMPANY:
FORMER CONFORMED NAME: ARVINAS INC.
DATE OF NAME CHANGE: 20181001
FORMER COMPANY:
FORMER CONFORMED NAME: ARVINAS HOLDING COMPANY, LLC
DATE OF NAME CHANGE: 20151015
4
1
wk-form4_1711052087.xml
FORM 4
X0508
4
2024-03-18
0
0001655759
ARVINAS, INC.
ARVN
0001369900
Berkowitz Noah
C/O ARVINAS, INC.
5 SCIENCE PARK, 395 WINCHESTER AVE.
NEW HAVEN
CT
06511
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-03-18
4
A
0
63452
0
A
63452
D
Stock Option (right to buy)
42.60
2024-03-18
4
A
0
93879
0
A
2034-03-17
Common Stock
93879
93879
D
The restricted stock units (each, an "RSU") were granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
The option was granted by the Issuer on March 18, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on March 18, 2025, with the remainder of the shares vesting in equal monthly installments following March 18, 2025 through March 18, 2028.
/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz
2024-03-21